Share This Page
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Guaifenesin And Dextromethorphan Hydrobromide, and what generic alternatives are available?
Guaifenesin And Dextromethorphan Hydrobromide is a drug marketed by Actavis Labs Fl, Amneal Pharms, Aurobindo Pharma, Dr Reddys, Perrigo R And D, and Sun Pharm. and is included in six NDAs.
The generic ingredient in GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE is dextromethorphan hydrobromide; guaifenesin. There are twenty-three drug master file entries for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the dextromethorphan hydrobromide; guaifenesin profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE?
- What are the global sales for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE?
- What is Average Wholesale Price for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE?
Summary for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE
| US Patents: | 0 |
| Applicants: | 6 |
| NDAs: | 6 |
US Patents and Regulatory Information for GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE
Guaifenesin and Dextromethorphan Hydrobromide Investment Analysis, Patent Risk, and Market Fundamentals
Guaifenesin and dextromethorphan hydrobromide are mature, low-cost over-the-counter active ingredients used in cough, cold and mucus-relief products. The combination has limited pharmaceutical patent value and no conventional prescription-drug exclusivity. Investment exposure is concentrated in brand equity, retail distribution, formulation execution, supply-chain reliability, private-label manufacturing and regulatory compliance.
The principal commercial products include Mucinex DM, Robitussin DM, store-brand equivalents and numerous liquid, tablet, capsule, extended-release and combination cold products. The market is competitive and price-sensitive. Long-term growth is more likely to come from premium dosage forms, extended-release delivery, retailer distribution and international expansion than from new chemical-entity economics.
What are guaifenesin and dextromethorphan hydrobromide used for?
Guaifenesin is an expectorant. It is intended to loosen phlegm and thin bronchial secretions, making mucus easier to remove through coughing.
Dextromethorphan hydrobromide is an antitussive. It suppresses the cough reflex and is used for temporary relief of cough caused by minor throat and bronchial irritation.
The combination addresses two symptoms at once:
| Active ingredient | Pharmacologic role | Commercial purpose |
|---|---|---|
| Guaifenesin | Expectorant | Mucus and chest congestion relief |
| Dextromethorphan hydrobromide | Antitussive | Cough suppression |
| Combination | Expectorant plus antitussive | Broad cough-and-chest-congestion positioning |
The products are generally marketed for adults and children above specified age thresholds, depending on the formulation and label. Pediatric labeling is a material regulatory issue because the FDA has warned against use of many cough and cold products in children younger than two and manufacturers commonly label products against use in children younger than four.[1]
What is the FDA regulatory status of the combination?
Guaifenesin and dextromethorphan hydrobromide are established OTC ingredients regulated through FDA nonprescription-drug rules rather than through a new prescription-drug approval pathway.
The relevant regulatory framework is the FDA’s OTC cough-and-cold monograph system, including the monograph provisions historically codified in 21 C.F.R. Part 341 and the newer administrative-order framework established by the Coronavirus Aid, Relief, and Economic Security Act.[2] Products that conform to the applicable monograph conditions can be marketed without an individual New Drug Application.
Key regulatory characteristics include:
- No prescription NDA exclusivity.
- No Hatch-Waxman exclusivity period for ordinary OTC monograph products.
- No need to obtain FDA approval for every private-label version if the product complies with the applicable requirements.
- Labeling, dosage, active-ingredient concentration, warnings, packaging and manufacturing controls remain subject to FDA enforcement.
- Combination products must satisfy the conditions applicable to each active ingredient and the permitted combination.
The regulatory barrier is therefore lower than for prescription pharmaceuticals, but noncompliance can trigger recalls, warning letters, import detention, retailer delisting and product liability exposure.
What patents protect guaifenesin and dextromethorphan hydrobromide products?
The active ingredients have limited patent protection as commercial assets because both are long-established compounds. The primary commercial barriers are formulation patents, trademarks, trade dress, manufacturing know-how and retail relationships.
Active-ingredient patent position
Guaifenesin has been used as an OTC expectorant for decades. Dextromethorphan has also been marketed for decades as an antitussive. Any original compound patent protection is long expired or commercially irrelevant in the United States.
The combination therefore does not have the patent profile of a modern prescription drug. A manufacturer can generally compete by producing an equivalent monograph-compliant product without taking a license from the owner of a branded product’s core active ingredients.
Formulation and delivery patents
The more relevant patent categories include:
- Extended-release guaifenesin tablets.
- Bilayer or multilayer tablets containing guaifenesin and dextromethorphan.
- Taste-masked liquid formulations.
- Abuse-deterrent or tamper-resistant dextromethorphan products.
- Stabilized liquid compositions.
- Tablet coatings and controlled-dissolution systems.
- Packaging and dosing systems.
- Combination products containing additional analgesic, decongestant or antihistamine ingredients.
These patents may create temporary differentiation, but they generally do not block all guaifenesin and dextromethorphan products. A competitor can often design around a particular release profile, excipient system, tablet architecture or packaging claim.
The strongest commercial formulation protection historically has been associated with extended-release products such as Mucinex DM. Even where formulation patents remain relevant, their value depends on claim scope, remaining patent term, enforceability and whether the competing product provides a legally distinct release profile.
What is the Orange Book status of guaifenesin and dextromethorphan hydrobromide?
Ordinary OTC monograph products are generally not treated like approved prescription products listed in the FDA Orange Book.
The FDA Orange Book principally identifies approved drug products, therapeutic-equivalence evaluations and listed patent or exclusivity information for products approved through applicable NDA or abbreviated pathways. A standard OTC monograph product does not receive the same Orange Book patent-listing structure as a prescription NDA product.[3]
Commercial implications include:
| Issue | Practical effect |
|---|---|
| Orange Book listing | Usually absent for ordinary OTC monograph products |
| Paragraph IV challenge | Generally not the central pathway |
| ANDA litigation | Usually not the primary competitive mechanism |
| Generic entry | Can occur through monograph compliance and private-label manufacturing |
| Patent risk | Concentrated in formulation, packaging and brand-specific claims |
| Exclusivity | No conventional NDA exclusivity for the monograph product |
Some prescription or NDA-approved products containing dextromethorphan, including products with specialized abuse-deterrent technology, may have a different regulatory and patent profile. Those products should not be analyzed as equivalent to ordinary OTC guaifenesin-dextromethorphan combinations.
When does guaifenesin and dextromethorphan lose exclusivity?
The core combination has no meaningful remaining chemical exclusivity in the United States. Market exclusivity is effectively governed by the OTC monograph, formulation patents, trademarks and distribution economics.
A simplified exclusivity timeline is:
| Period | Commercial condition |
|---|---|
| Original compound development | Historical patent protection |
| Mature OTC adoption | Active ingredients become broadly available |
| Brand expansion | Manufacturers develop liquid, tablet and extended-release products |
| Current market | Competition is primarily generic, private-label and brand-based |
| Future | Product-level differentiation depends on formulation, packaging, claims and channel access |
There is no single “loss of exclusivity” date comparable to the expiry of a prescription product’s composition-of-matter patent. A branded product can lose share long before any formulation patent expires because retailers can introduce equivalent store-brand products.
Which companies compete in the market?
The main competitive groups are branded consumer-health companies, generic OTC manufacturers, contract manufacturers and retailers.
Major branded products
| Product or brand | Principal company or commercial owner | Positioning |
|---|---|---|
| Mucinex DM | Reckitt | Extended-release cough and mucus relief |
| Robitussin DM | Haleon | Liquid and other cough-relief formats |
| Store-brand equivalents | CVS, Walgreens, Walmart, Target and other retailers | Low-price substitution |
| Generic OTC products | Perrigo, Pharmaceutics and other manufacturers | Retail and private-label supply |
| International brands | Varies by country | Local regulatory and distribution models |
Brand ownership, licensing and manufacturing arrangements can vary by country and product format. Consumer-health companies often use third-party manufacturing, regional licensees and retailer-specific supply contracts.
The competitive advantage is rarely the API itself. It is more often a combination of:
- Shelf placement.
- Brand recognition.
- Advertising.
- Retailer distribution.
- Product availability during respiratory-illness seasons.
- Extended-release convenience.
- Taste and dosage-form performance.
- Supply reliability.
- Pricing and promotions.
How strong is the patent estate for guaifenesin and dextromethorphan products?
The patent estate is weak for the basic active-ingredient combination and stronger only at the product-specific formulation level.
A commercial assessment can be summarized as follows:
| Patent category | Relative strength | Investment relevance |
|---|---|---|
| Guaifenesin composition of matter | Very low | No meaningful barrier |
| Dextromethorphan composition of matter | Very low | No meaningful barrier |
| Basic combination claims | Low | Easy substitution risk |
| Extended-release formulations | Moderate for specific products | May protect premium positioning |
| Taste-masked liquids | Low to moderate | Design-around risk |
| Abuse-deterrent systems | Moderate to high if clinically and technically differentiated | Relevant in specialized products |
| Packaging and dosing systems | Low to moderate | Narrow scope |
| Trademarks and trade dress | High for established brands | Important commercial barrier |
| Manufacturing know-how | Moderate | Can affect quality, cost and supply |
Patent strength should be evaluated claim by claim. A patent covering a particular matrix tablet or dissolution profile does not necessarily prevent a competing immediate-release liquid or a different extended-release formulation.
What generic entry risks exist?
Generic and private-label entry risk is high. Retailers can source products containing the same active ingredients from multiple contract manufacturers, subject to FDA compliance and supply availability.
The main entry scenarios are:
Immediate-release private-label launch
This is the lowest-risk entry route for a competitor. A manufacturer can develop a compliant tablet, capsule or liquid using established ingredients and sell through a retailer or distributor.
Extended-release design-around
A competitor can target an extended-release branded product with a different excipient system, tablet structure or dissolution profile. The technical burden is higher, but the commercial opportunity is also greater because extended-release products typically command stronger pricing.
Retailer substitution
A retailer can replace a branded product with a store-brand equivalent while preserving the same therapeutic category and shelf location. This creates direct margin pressure on branded products.
Combination-product expansion
Manufacturers can add acetaminophen, phenylephrine, chlorpheniramine or other permitted ingredients to create adjacent cough-and-cold products. This broadens the competitive set but also increases labeling and regulatory complexity.
Seasonal inventory competition
Respiratory products experience demand surges. Manufacturers with reliable supply can gain share during shortages or seasonal peaks. Conversely, production interruptions can rapidly damage shelf position.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are more important than molecule-level intellectual property.
Active pharmaceutical ingredient supply
Guaifenesin and dextromethorphan hydrobromide are commodity-like APIs. Input costs, supplier concentration, import exposure, quality audits and FDA compliance affect margins.
Liquid manufacturing
Liquid products require control of:
- Solubility and suspension behavior.
- Flavor and bitterness.
- Preservative systems.
- Microbial limits.
- Viscosity.
- Dose uniformity.
- Child-resistant packaging.
- Measuring devices.
Dextromethorphan’s bitter taste increases the formulation burden in liquid products. A superior taste profile can support brand retention but is usually difficult to protect broadly with patents.
Extended-release manufacturing
Extended-release tablets require dissolution testing, process control and consistent release performance. Scale-up failures can produce batch variability, recalls or regulatory observations.
Contract manufacturing
Many private-label products are produced by contract manufacturers. The key diligence questions are facility history, warning letters, recall record, capacity utilization, API sourcing and ability to manage seasonal demand.
What patent litigation affects these products?
The litigation risk is materially lower than in prescription-drug markets. There is generally no recurring Paragraph IV litigation cycle around the basic guaifenesin-dextromethorphan combination.
Potential disputes are more likely to involve:
- Formulation patents.
- Trade dress.
- Trademark infringement.
- False advertising.
- Product labeling.
- Contract manufacturing.
- Supply agreements.
- Product liability.
- Retailer or distributor relationships.
A competitor launching a simple monograph-compliant product is more likely to face commercial and branding disputes than a traditional Orange Book patent suit.
Settlement agreements can arise in formulation or trademark disputes, but settlements do not create market-wide exclusivity for the active ingredients. Their value is limited to the parties, products, claims and jurisdictions covered by the agreement.
What is the revenue exposure for branded manufacturers?
Revenue exposure is meaningful for consumer-health companies but usually modest at the consolidated pharmaceutical level.
For Reckitt, Mucinex is part of a broader consumer-health portfolio that includes hygiene, wellness and household brands. For Haleon, Robitussin is part of a diversified portfolio spanning pain relief, oral health, vitamins and other consumer-health categories.[4,5]
The investment sensitivity is driven by:
- Seasonal respiratory demand.
- Retail scanner trends.
- Advertising efficiency.
- Gross-margin compression.
- Private-label share.
- Product availability.
- Retailer inventory levels.
- Consumer trade-down during inflationary periods.
- Regulatory restrictions on pediatric cough-and-cold products.
- Product recalls or manufacturing interruptions.
The combination can support attractive brand margins when extended-release or liquid products command a premium. Those margins are vulnerable to store-brand substitution because the underlying APIs are inexpensive and widely available.
How does Mucinex DM compare with Robitussin DM?
| Factor | Mucinex DM | Robitussin DM |
|---|---|---|
| Primary brand owner | Reckitt | Haleon |
| Core positioning | Extended-release mucus and cough relief | Cough relief, with strong liquid heritage |
| Principal dosage-form advantage | Tablet convenience and longer-duration positioning | Liquid familiarity and formulation breadth |
| Patent relevance | Product-specific formulation claims may matter | Brand, formulation and packaging claims |
| Generic substitution risk | High | High |
| Retail dependence | High | High |
| Main commercial moat | Brand recognition and extended-release positioning | Brand recognition, liquid familiarity and distribution |
Mucinex DM is more exposed to competition in extended-release tablets and store-brand equivalents. Robitussin DM is more exposed to liquid-product substitution, taste comparisons, retailer pricing and manufacturing execution.
Neither brand has a molecule-level moat. Their defenses are commercial rather than foundational.
What is the likely generic launch scenario?
The most likely launch scenario is gradual private-label substitution rather than a single disruptive generic event.
A typical sequence is:
- A contract manufacturer supplies a monograph-compliant equivalent.
- A national or regional retailer introduces a store-brand product.
- The retailer discounts the product against the branded equivalent.
- The branded company responds through promotions, package-size changes or advertising.
- Share shifts toward private label, especially in price-sensitive channels.
- The branded company retains premium share through extended-release claims, convenience, taste and recognition.
A second scenario involves a formulation-focused entrant targeting premium extended-release products. This entrant would face greater technical and patent risk but could obtain stronger margins than an immediate-release private-label supplier.
What licensing deals are relevant?
Licensing is more likely to involve trademarks, geographic rights, contract manufacturing or consumer-health portfolios than the active ingredients.
Potential deal structures include:
- Trademark licensing for regional markets.
- Supply agreements with OTC manufacturers.
- Retailer-exclusive products.
- Co-branded products.
- Portfolio acquisitions.
- Contract manufacturing and distribution agreements.
- Technology licenses for taste masking, controlled release or abuse deterrence.
An investment review should distinguish between a trademark license and a technology license. A trademark license may provide market access but little technical protection. A formulation license may provide stronger differentiation but can carry royalty, manufacturing and freedom-to-operate constraints.
What geographic coverage does the product have?
Guaifenesin and dextromethorphan products are marketed widely in North America and other international markets, but regulatory status differs by jurisdiction.
Key geographic issues include:
| Region | Main consideration |
|---|---|
| United States | OTC monograph compliance, FDA labeling and manufacturing controls |
| Canada | Health Canada nonprescription-drug requirements and bilingual labeling |
| European Union | National or harmonized medicinal-product requirements; cough products may be regulated differently from U.S. OTC products |
| Asia-Pacific | Country-specific registration, import and labeling requirements |
| Emerging markets | Local distributor strength, price controls and counterfeit risk |
A product marketed legally in the United States cannot automatically be exported under the same label or dosage instructions. Geographic expansion depends on local monographs, national registrations, permitted concentrations and pediatric rules.
What are the principal investment risks and catalysts?
Principal risks
- High generic and private-label substitution.
- Low barriers to API sourcing.
- Retailer bargaining power.
- Product recalls.
- FDA manufacturing observations.
- Pediatric safety restrictions.
- Seasonal demand volatility.
- Consumer movement toward non-drug remedies.
- Supply-chain disruption.
- Litigation involving branding or formulation claims.
- Margin erosion from promotional pricing.
Potential catalysts
- Strong respiratory-season sell-through.
- Successful premium extended-release launches.
- Improved liquid taste or dosing systems.
- Retail distribution gains.
- Private-label manufacturing contracts.
- International expansion.
- Acquisition of a strong consumer-health brand.
- Manufacturing-cost reductions.
- New abuse-deterrent or specialty dextromethorphan technology.
The most attractive investment exposure is generally not ownership of the old active ingredients. It is ownership of a differentiated consumer-health brand, a high-quality OTC manufacturing platform or a scalable retail distribution network.
Key Takeaways
- Guaifenesin and dextromethorphan hydrobromide are mature OTC active ingredients with minimal core patent value.
- The FDA framework is primarily monograph-based, not NDA-based.
- Ordinary products generally do not have the Orange Book exclusivity profile of prescription drugs.
- Paragraph IV litigation is not the main market-entry risk.
- Formulation patents may protect specific extended-release, taste-masked or abuse-deterrent products.
- Mucinex DM and Robitussin DM compete primarily through brand, distribution, dosage form and consumer preference.
- Generic and private-label entry risk is high.
- Manufacturing reliability, retailer access and intellectual-property clearance are more important than composition-of-matter patents.
- Revenue exposure is concentrated in consumer-health businesses and is sensitive to seasonality, trade-down and retail pricing.
- The strongest investment thesis is based on brand or platform economics, not the active ingredients themselves.
FAQs
Is guaifenesin and dextromethorphan hydrobromide a generic drug?
It is a combination of established OTC active ingredients. Products can be marketed as branded, generic or private-label products when they meet applicable FDA requirements.
Does Mucinex DM have patent protection?
Mucinex DM may have product-specific formulation or delivery patents, but those patents do not create broad protection over guaifenesin, dextromethorphan or all combination products.
Can a retailer sell a store-brand equivalent?
Yes. Retailers commonly sell private-label products containing the same active ingredients, provided the products comply with applicable FDA monograph, labeling, manufacturing and packaging requirements.
Is dextromethorphan hydrobromide subject to abuse-related regulation?
Dextromethorphan has known misuse potential, particularly at high doses. States and retailers may impose additional sales restrictions, and product manufacturers must manage warnings, packaging and marketing compliance.
Is the combination attractive for pharmaceutical investment?
The combination is more attractive as a consumer-health, contract-manufacturing or retail-distribution opportunity than as a traditional patent-pharmaceutical investment. Core ingredient economics are mature, while brand and channel economics remain commercially relevant.
References
-
U.S. Food and Drug Administration. (2024). Use caution when giving cough and cold products to kids. FDA.
-
U.S. Food and Drug Administration. (2024). Over-the-counter monograph drugs. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
-
Reckitt Benckiser Group plc. (2024). Annual report and financial statements 2023. Reckitt.
-
Haleon plc. (2024). Annual report and financial statements 2023. Haleon.
-
U.S. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. Government Publishing Office.
-
U.S. National Library of Medicine. (2024). DailyMed: Guaifenesin and dextromethorphan hydrobromide drug labels. National Institutes of Health.
More… ↓
